COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,800 Articles (22,527 medRxiv, 8,273 bioRxiv)

Most recent first Previous |  Page 1766: Articles 17651-17660  | Next

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., Albert, M., Donati, F., Behillil, S., Enouf, V., Marianne, M., Gonzalez, M., De Seze, J., Pere, H., Veyer, D., Seve, A., Simon-Loriere, E., Fafi-Kremer, S., Stefic, K., Mouquet, H., Hocqueloux, L., van der Werf, S., Prazuck, T., Schwartz, O.
10.1101/2021.02.12.430472 — Posted: 2021-02-12
Physical phenotype of blood cells is altered in COVID-19
Kubankova, M., Hohberger, B., Hoffmanns, J., Fuerst, J., Hermann, M., Guck, J., Krater, M.
10.1101/2021.02.12.429482 — Posted: 2021-02-12
Surface-aerosol stability and pathogenicity of diverse MERS-CoV strains from 2012 - 2018
van Doremalen, N., Letko, M. C., Fischer, R., Bushmaker, T., Yinda, K. C., Schulz, J., Seifert, S. N., Kim, N. J., Hemida, M. G., Kayali, G., Park, W. B., Perera, R., Tamin, A., Thornburg, N. J., Tong, S., Queen, K., Van Kerkhove, M. D., Choi, Y. K., Oh, M.-d., Assiri, A. M., Peiris, J. S. M., Gerber, S., Munster, V.
10.1101/2021.02.11.429193 — Posted: 2021-02-12
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Liu, H., Yuan, M., Huang, D., Bangaru, S., Lee, C.-C. D., Peng, L., Zhu, X., Nemazee, D., van Gils, M. J., Sanders, R. W., Kornau, H.-C., Reincke, S. M., Pruss, H., Kreye, J., Wu, N. C., Ward, A. B., Wilson, I. A.
10.1101/2021.02.11.430866 — Posted: 2021-02-12
Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic
Farcet, M. R., Karbiener, M., Schwaiger, J., Ilk, R., Kreil, T. R.
10.1101/2021.02.12.430933 — Posted: 2021-02-12
A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes reveals age-related differences in convalescent COVID-19 patients
Bieberich, F., Vazquez-Lombardi, R., Yermanos, A., Ehling, R. A., Wagner, B., Kapetanovic, E., Di Roberto, R. B., Savic, M., Rudolf, F., Reddy, S. T.
10.1101/2021.02.12.430907 — Posted: 2021-02-12
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19
Feyaerts, D., Hedou, J., Gillard, J., Chen, H., Tsai, E. S., Peterson, L. S., Ando, K., Manohar, M., Do, E., Dhondalay, G. K. R., Fitzpatrick, J., Artandi, M., Chang, I., Snow, T. T., Chinthrajah, R. S., Warren, C. M., Wittman, R., Meyerowitz, J. G., Ganio, E. A., Stelzer, I. A., Han, X., Verdonk, F., Gaudilliere, D. K., Mukherjee, N., Tsai, A. S., Rumer, K. K., Jiang, S. J., Valdes-Ferrer, S. I., Kelly, J. D., Furman, D., Aghaeepour, N., Angst, M. S., Boyd, S. D., Pinsky, B. A., Nolan, G. P., Nadeau, K. C., Gaudilliere, B., McIlwain, D. R.
10.1101/2021.02.09.430269 — Posted: 2021-02-12
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Horby, P. W., Campbell, M., Staplin, N., Spata, E., Emberson, J. R., Pessoa-Amorim, G., Peto, L., Brightling, C. E., Sarkar, R., Thomas, K., Jeebun, V., Ashish, A., Tully, R., Chadwick, D., Sharafat, M., Stewart, R., Rudran, B., Baillie, J. K., Buch, M. H., Chappell, L. C., Day, J. N., Furst, S. N., Jaki, T., Jeffery, K., Juszczak, E., Lim, W. S., Montgomery, A., Mumford, A., Rowan, K., Thwaites, G., Mafham, M., Haynes, R., Landray, M. J.
10.1101/2021.02.11.21249258 — Posted: 2021-02-11 Discussion: Offsite
SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination
Hoffmann, M., Arora, P., Gross, R., Seidel, A., Hoernich, B., Hahn, A., Krueger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., Winkler, M. S., Schulz, S., Jaeck, H.-M., Jahrsdoerfer, B., Schrezenmeier, H., Mueller, M., Kleger, A., Muench, J., Poehlmann, S.
10.1101/2021.02.11.430787 — Posted: 2021-02-11
Data-driven analysis of COVID-19 reveals specific severity patterns distinct from the temporal immune response
Lim, J., Carissimo, G., Chan, Y.-H., Fong, S.-W., Lee, W. W., Tan, S.-Y., Lye, D. C., Young, B. E., Renia, L., Fong-Poh NG, L., Rotzschke, O., Puan, K. J., Wang, L. W., Teng, K. W. W., Loh, C. Y., Tan, K. P., Poh, C. M., Lee, C. Y.-P., Yeo, N. K.-W., Chee, R. S.-L., Amrun, S. N., Chang, Z. W., Tay, M. Z., Torres-Ruesta, A., Leo Fernandez, N., How, W., K. Andiappan, A., Duan, K., Yan, G., Kalimuddin, S., Leo, Y.-S., Ong, S. W. X., Lee, B.
10.1101/2021.02.10.430668 — Posted: 2021-02-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).